Disclosed are (i) compounds of a steroid, a &bgr;-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO
2
group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, &bgr;-agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO
2
moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO
+
) or nitroxyl (NO
−
), or as the neutral species, nitric oxide (NO•) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.
本发明涉及(i)类
固醇、&bgr;-激动剂、抗
胆碱能药、肥大细胞稳定剂和
磷酸二酯酶(PDE)
抑制剂的化合物,直接或间接连接到NO或
NO2基团或在体内刺激内源性NO或EDRF的产生的基团;(ii)类
固醇、&bgr;-激动剂、抗
胆碱能药、肥大细胞稳定剂和PDE
抑制剂的组合物,可选择性地被替换为至少一个NO或 基团或在体内刺激内源性NO或EDRF的产生的基团,以及捐赠、转移或释放
硝酸盐作为带电物种,即亚硝基阳离子(NO+)或亚硝基(NO−),或作为中性物种,
硝酸盐(NO•)或在体内刺激内源性NO或EDRF的产生的化合物;以及(iii)它们在预防和/或治疗呼吸系统疾病中的用途。